SCHEMBL771679

SCHEMBL771679

O=C(O)NCCC(=O)N1CCCC2CCCCC21

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
HSD11B1 P28845 6/20 0.40
DPP4 P27487 5/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HSD17B1 P14061 1/20 0.39
ACE P12821 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769965 0.88 NPC1 (0.50) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL772214 0.85 DPP4 (0.47) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL771394 0.84 HSD11B1 (0.42) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL771374 0.84 DPP4 (0.48) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL771464 0.84 DRD2 (0.51) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL770672 0.83 DRD2 (0.40) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL770799 0.83 DPP4 (0.60) NPC1RAB9ASMN1; SMN2HSD11B1DPP4
SCHEMBL770027 0.82 DRD2 (0.39) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL770636 0.82 EPHX2 (0.51) NPC1RAB9ASMN1; SMN2
SCHEMBL771491 0.82 ALDH1A1 (0.47) NPC1RAB9ASMN1; SMN2DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.